951 related articles for article (PubMed ID: 8081034)
21. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
22. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
Boege F
Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
[TBL] [Abstract][Full Text] [Related]
23. Multilevel therapeutic targeting by topoisomerase inhibitors.
Smith PJ; Souès S
Br J Cancer Suppl; 1994 Sep; 23():S47-51. PubMed ID: 8075006
[TBL] [Abstract][Full Text] [Related]
24. Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity.
Utsugi T; Demuth S; Hanna N
Cancer Res; 1989 Mar; 49(6):1429-33. PubMed ID: 2538225
[TBL] [Abstract][Full Text] [Related]
25. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
26. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.
Fox ME; Smith PJ
Cancer Res; 1990 Sep; 50(18):5813-8. PubMed ID: 2168281
[TBL] [Abstract][Full Text] [Related]
27. Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity.
Poot M; Hiller KH; Heimpel S; Hoehn H
Exp Cell Res; 1995 May; 218(1):326-30. PubMed ID: 7537696
[TBL] [Abstract][Full Text] [Related]
28. Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells.
Muscarella DE; Rachlinski MK; Sotiriadis J; Bloom SE
Exp Cell Res; 1998 Jan; 238(1):155-67. PubMed ID: 9457068
[TBL] [Abstract][Full Text] [Related]
29. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
30. Binding of DNA topoisomerases I and II to replication origins.
Falaschi A
Methods Mol Biol; 2009; 582():131-43. PubMed ID: 19763947
[TBL] [Abstract][Full Text] [Related]
31. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.
Liu LF; D'Arpa P
Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311
[No Abstract] [Full Text] [Related]
32. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
33. DNA topoisomerases in cancer therapy.
Lock RB; Ross WE
Anticancer Drug Des; 1987 Oct; 2(2):151-64. PubMed ID: 2835059
[TBL] [Abstract][Full Text] [Related]
34. Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.
Mattern MR; Tan KB; Zimmerman JP; Mong SM; Bartus JO; Hofmann GA; Drake FH; Johnson RK; Crooke ST; Mirabelli CK
Anticancer Drug Des; 1989 Aug; 4(2):107-24. PubMed ID: 2478139
[TBL] [Abstract][Full Text] [Related]
35. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
[TBL] [Abstract][Full Text] [Related]
36. DNA topoisomerase II as a potential factor in drug resistance of human malignancies.
Potmesil M; Hsiang YH; Liu LF; Wu HY; Traganos F; Bank B; Silber R
NCI Monogr; 1987; (4):105-9. PubMed ID: 3041236
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
38. Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity.
Habermeyer M; Fritz J; Barthelmes HU; Christensen MO; Larsen MK; Boege F; Marko D
Chem Res Toxicol; 2005 Sep; 18(9):1395-404. PubMed ID: 16167831
[TBL] [Abstract][Full Text] [Related]
39. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
40. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]